197 related articles for article (PubMed ID: 33683975)
1. Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss.
Fan Y; Fan H; Quan Z; Wu X
Cancer Invest; 2021 May; 39(5):423-434. PubMed ID: 33683975
[TBL] [Abstract][Full Text] [Related]
2. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
4. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Mu P; Zhang Z; Benelli M; Karthaus WR; Hoover E; Chen CC; Wongvipat J; Ku SY; Gao D; Cao Z; Shah N; Adams EJ; Abida W; Watson PA; Prandi D; Huang CH; de Stanchina E; Lowe SW; Ellis L; Beltran H; Rubin MA; Goodrich DW; Demichelis F; Sawyers CL
Science; 2017 Jan; 355(6320):84-88. PubMed ID: 28059768
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma.
Zoumpoulidou G; Alvarez-Mendoza C; Mancusi C; Ahmed RM; Denman M; Steele CD; Tarabichi M; Roy E; Davies LR; Manji J; Cristalli C; Scotlandi K; Pillay N; Strauss SJ; Mittnacht S
Nat Commun; 2021 Dec; 12(1):7064. PubMed ID: 34862364
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Schwermer M; Hiber M; Dreesmann S; Rieb A; Theißen J; Herold T; Schramm A; Temming P; Steenpass L
Exp Cell Res; 2019 Feb; 375(2):92-99. PubMed ID: 30584916
[TBL] [Abstract][Full Text] [Related]
8. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side-by-side comparison in karyotypically normal cells.
Andersson N; Saba KH; Magnusson L; Nilsson J; Karlsson J; Nord KH; Gisselsson D
Genes Chromosomes Cancer; 2023 Feb; 62(2):93-100. PubMed ID: 36124964
[TBL] [Abstract][Full Text] [Related]
10. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis.
Wang ME; Chen J; Lu Y; Bawcom AR; Wu J; Ou J; Asara JM; Armstrong AJ; Wang Q; Li L; Wang Y; Huang J; Chen M
J Clin Invest; 2023 May; 133(10):. PubMed ID: 36928314
[TBL] [Abstract][Full Text] [Related]
11. PARP1 Is Required for ATM-Mediated p53 Activation and p53-Mediated Gene Expression after Ionizing Radiation.
Gajewski S; Hartwig A
Chem Res Toxicol; 2020 Jul; 33(7):1933-1940. PubMed ID: 32551582
[TBL] [Abstract][Full Text] [Related]
12. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
13. The P53-P21-RB1 pathway promotes BRD4 degradation in liver cancer through USP1.
Li N; Zhang E; Li Z; Lv S; Zhao X; Ke Q; Zou Q; Li W; Wang Y; Guo H; Song T; Sun L
J Biol Chem; 2024 Mar; 300(3):105707. PubMed ID: 38309505
[TBL] [Abstract][Full Text] [Related]
14. RB1 and TP53 pathways in radiation-induced sarcomas.
Gonin-Laurent N; Hadj-Hamou NS; Vogt N; Houdayer C; Gauthiers-Villars M; Dehainault C; Sastre-Garau X; Chevillard S; Malfoy B
Oncogene; 2007 Sep; 26(41):6106-12. PubMed ID: 17369843
[TBL] [Abstract][Full Text] [Related]
15. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
16. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
[TBL] [Abstract][Full Text] [Related]
17. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
18. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
[TBL] [Abstract][Full Text] [Related]
19. Suppression of RAD21 Induces Senescence of MDA-MB-231 Human Breast Cancer Cells Through RB1 Pathway Activation Via c-Myc Downregulation.
Zhu S; Zhao L; Li Y; Hou P; Yao R; Tan J; Liu D; Han L; Huang B; Lu J; Zhang Y
J Cell Biochem; 2016 Jun; 117(6):1359-69. PubMed ID: 26529363
[TBL] [Abstract][Full Text] [Related]
20. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
